Mutations in specific codons of the KRAS oncogene are associated with variable resistance to neoadjuvant chemoradiation therapy in patients with rectal adenocarcinoma.

ABSTRACT:

Background

Mutations in KRAS and TP53 are common in colorectal carcinogenesis and are associated with resistance to therapy. Rectal cancers carrying both mutations are less likely to respond to neoadjuvant chemoradiation therapy (CRT) compared with wild-type tumors. Codon-specific KRAS mutations are associated with variable resistance to targeted therapies, but their association with rectal cancer response to CRT remains unclear. Our objective was to establish a correlation between specific KRAS mutations and rectal cancer response to CRT and to investigate if the correlation was related to a different association between KRAS and TP53 mutations.

Methods

A total of 148 stage II-III rectal cancer patients underwent preoperative CRT followed by surgery. DNA was extracted from

SUBMITTER: Duldulao MP 

PROVIDER: S-EPMC5584556 | biostudies-literature | 2013 Jul

REPOSITORIES: biostudies-literature